Spyre Therapeutics (SYRE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $79.90, -0.25% vs the prior close of $80.10.
- Volume 1.27M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SYRE ends flat (-0.2%) to $79.90. Closed at $79.90, -0.25% vs the prior close of $80.10. Day range $78.12–$80.52, opened at $80.21.
SYRE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SYRE ends flat (-0.2%) to $79.90
- Closed at $79.90, -0.25% vs the prior close of $80.10. Day range $78.12–$80.52, opened at $80.21.
- Volume was 1.27M shares, 1.0x its 50-day average of 1.29M.
- Price is -13.4% vs its 50-day average ($92.31) and +14.0% vs its 200-day average ($70.09).
- 52-week range $21.15–$110.18; today's close sits at 66% of that range, 27.5% below the 52-week high.
Oct 15, 2026 — SYRE rises 1.9% to $80.10
- Closed at $80.10, +1.87% vs the prior close of $78.63. Day range $76.87–$80.88, opened at $76.87.
- Volume was 1.15M shares, 0.9x its 50-day average of 1.28M.
- Price is -13.7% vs its 50-day average ($92.78) and +14.7% vs its 200-day average ($69.85).
- 52-week range $21.01–$110.18; today's close sits at 66% of that range, 27.3% below the 52-week high.
Oct 14, 2026 — SYRE dips 2.3% to $78.63, a 3-month low
- Closed at $78.63, -2.26% vs the prior close of $80.45. Day range $77.95–$82.45, opened at $80.13.
- Volume was 1.62M shares, 1.3x its 50-day average of 1.27M.
- Price is -15.7% vs its 50-day average ($93.27) and +12.9% vs its 200-day average ($69.61).
- 52-week range $18.71–$110.18; today's close sits at 66% of that range, 28.6% below the 52-week high.
Oct 13, 2026 — SYRE slides 6.3% to $80.45
- Closed at $80.45, -6.34% vs the prior close of $85.90. Day range $80.45–$85.32, opened at $85.12.
- Volume was 1.44M shares, 1.1x its 50-day average of 1.26M.
- Price is -14.2% vs its 50-day average ($93.79) and +15.9% vs its 200-day average ($69.39).
- 52-week range $18.12–$110.18; today's close sits at 68% of that range, 27.0% below the 52-week high.
Oct 12, 2026 — SYRE ends flat (+0.2%) to $85.90
- Closed at $85.90, +0.25% vs the prior close of $85.69. Day range $84.21–$86.62, opened at $86.30.
- Volume was 873.90K shares, 0.7x its 50-day average of 1.25M.
- Price is -8.7% vs its 50-day average ($94.08) and +24.2% vs its 200-day average ($69.15).
- 52-week range $18.12–$110.18; today's close sits at 74% of that range, 22.0% below the 52-week high.
Oct 9, 2026 — SYRE jumps 7.2% to $85.69
- Closed at $85.69, +7.25% vs the prior close of $79.90. Day range $78.73–$86.22, opened at $79.90.
- Volume was 1.12M shares, 0.9x its 50-day average of 1.25M.
- Price is -9.2% vs its 50-day average ($94.33) and +24.4% vs its 200-day average ($68.89).
- 52-week range $17.65–$110.18; today's close sits at 74% of that range, 22.2% below the 52-week high.
Oct 8, 2026 — SYRE dips 1.2% to $79.90, a 3-month low on 1.9x normal volume
- Closed at $79.90, -1.18% vs the prior close of $80.85. Day range $77.05–$80.91, opened at $79.58.
- Volume was 2.33M shares, 1.9x its 50-day average of 1.22M — unusually heavy trading.
- Price is -15.6% vs its 50-day average ($94.65) and +16.4% vs its 200-day average ($68.63).
- 52-week range $16.04–$110.18; today's close sits at 68% of that range, 27.5% below the 52-week high.
Oct 7, 2026 — SYRE rises 0.9% to $80.85 on 2.3x normal volume
- Closed at $80.85, +0.92% vs the prior close of $80.11. Day range $78.00–$82.22, opened at $78.91.
- Volume was 2.72M shares, 2.3x its 50-day average of 1.20M — unusually heavy trading.
- Price is -14.9% vs its 50-day average ($95.01) and +18.2% vs its 200-day average ($68.40).
- 52-week range $16.00–$110.18; today's close sits at 69% of that range, 26.6% below the 52-week high.
- SEC filings that day: 8-K.
Oct 6, 2026 — SYRE slides 13.6% to $80.11, a 3-month low on 3.8x normal volume
- Closed at $80.11, -13.60% vs the prior close of $92.72. Day range $79.36–$92.08, opened at $92.08.
- Volume was 4.25M shares, 3.8x its 50-day average of 1.13M — unusually heavy trading.
- Price is -16.0% vs its 50-day average ($95.39) and +17.5% vs its 200-day average ($68.16).
- 52-week range $15.86–$110.18; today's close sits at 68% of that range, 27.3% below the 52-week high.
- SEC filings that day: 424B5.
Oct 5, 2026 — SYRE dips 0.5% to $92.72
- Closed at $92.72, -0.50% vs the prior close of $93.19. Day range $89.49–$95.01, opened at $93.02.
- Volume was 642.80K shares, 0.6x its 50-day average of 1.13M — lighter than usual.
- Price is -3.2% vs its 50-day average ($95.79) and +36.5% vs its 200-day average ($67.92).
- 52-week range $15.86–$110.18; today's close sits at 81% of that range, 15.8% below the 52-week high.
- SEC filings that day: 424B5.
Oct 2, 2026 — SYRE jumps 3.6% to $93.19, a 1-month high, 3 up days in a row
- Closed at $93.19, +3.63% vs the prior close of $89.93. Day range $90.48–$95.27, opened at $91.16.
- Volume was 1.24M shares, 1.1x its 50-day average of 1.12M.
- Price is -2.9% vs its 50-day average ($95.98) and +37.8% vs its 200-day average ($67.63).
- 52-week range $15.86–$110.18; today's close sits at 82% of that range, 15.4% below the 52-week high.
- That makes 3 straight gains.
SYRE latest news & SEC filings
Every SEC filing by or about SYRE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Oct 6, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 5, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- King-Jones Heidy converted options/RSUs into 28,933 shares at $14.50 (≈$419.53K) on Oct 1, 2026; now holds 31,778
- King-Jones Heidy sold 400 shares at $89.24 (≈$35.70K) on Oct 1, 2026; now holds 31,378
- King-Jones Heidy sold 16,605 shares at $90.35 (≈$1.50M) on Oct 1, 2026; now holds 14,773
- King-Jones Heidy sold 7,228 shares at $91.35 (≈$660.28K) on Oct 1, 2026; now holds 7,545
- King-Jones Heidy sold 2,100 shares at $92.70 (≈$194.67K) on Oct 1, 2026; now holds 5,445
- King-Jones Heidy sold 2,600 shares at $93.46 (≈$243.00K) on Oct 1, 2026; now holds 2,845
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Turtle Cameron sold 600 shares at $89.14 (≈$53.48K) on Oct 1, 2026; now holds 551,940
- Turtle Cameron sold 2,683 shares at $90.10 (≈$241.74K) on Oct 1, 2026; now holds 549,257
- Turtle Cameron sold 2,638 shares at $91.49 (≈$241.35K) on Oct 1, 2026; now holds 546,619
- Turtle Cameron sold 3,989 shares at $92.31 (≈$368.22K) on Oct 1, 2026; now holds 542,630
- Turtle Cameron sold 4,990 shares at $93.37 (≈$465.92K) on Oct 1, 2026; now holds 537,640
- Turtle Cameron sold 100 shares at $93.91 (≈$9.39K) on Oct 1, 2026; now holds 537,540
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Burrows Scott L converted options/RSUs into 17,500 shares at $14.50 (≈$253.75K) on Sep 30, 2026; now holds 97,262
- Burrows Scott L sold 17,500 shares at $89.89 (≈$1.57M) on Sep 30, 2026; now holds 79,762
- Burrows Scott L converted options/RSUs into 7,500 shares at $14.50 (≈$108.75K) on Oct 1, 2026; now holds 87,262
- Burrows Scott L sold 600 shares at $89.07 (≈$53.44K) on Oct 1, 2026; now holds 86,662
- Burrows Scott L sold 1,500 shares at $90.27 (≈$135.41K) on Oct 1, 2026; now holds 85,162
- Burrows Scott L sold 2,100 shares at $91.92 (≈$193.03K) on Oct 1, 2026; now holds 83,062
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 1, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade SYRE
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Apr 13, 2026, Feb 19, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.73% (largest 13.6%).
- Liquidity: about 1.52M shares (≈$121.41M) trade per day on average.
- 52-week position: $79.90 vs a range of $21.15–$110.18 (66% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Scott L Burrows sold 18,232 shares on Sep 2, 2026.
- Latest filings: 8-K Oct 7, 2026; 8-K Sep 8, 2026; 8-K Aug 25, 2026.
- Share count: 88.17M shares outstanding (Jul 28, 2026), +46.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SYRE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 80.21 | 80.52 | 78.12 | 79.90 | 1.27M |
| Oct 15, 2026 | 76.87 | 80.88 | 76.87 | 80.10 | 1.15M |
| Oct 14, 2026 | 80.13 | 82.45 | 77.95 | 78.63 | 1.62M |
| Oct 13, 2026 | 85.12 | 85.32 | 80.45 | 80.45 | 1.44M |
| Oct 12, 2026 | 86.30 | 86.62 | 84.21 | 85.90 | 873.90K |
| Oct 9, 2026 | 79.90 | 86.22 | 78.73 | 85.69 | 1.12M |
| Oct 8, 2026 | 79.58 | 80.91 | 77.05 | 79.90 | 2.33M |
| Oct 7, 2026 | 78.91 | 82.22 | 78.00 | 80.85 | 2.72M |
| Oct 6, 2026 | 92.08 | 92.08 | 79.36 | 80.11 | 4.25M |
| Oct 5, 2026 | 93.02 | 95.01 | 89.49 | 92.72 | 642.80K |
| Oct 2, 2026 | 91.16 | 95.27 | 90.48 | 93.19 | 1.24M |
| Oct 1, 2026 | 89.13 | 94.06 | 87.25 | 89.93 | 1.66M |
| Sep 30, 2026 | 88.64 | 95.08 | 88.00 | 89.03 | 2.10M |
| Sep 29, 2026 | 85.09 | 86.64 | 83.25 | 84.72 | 1.05M |
| Sep 28, 2026 | 84.72 | 87.12 | 84.00 | 85.79 | 1.05M |
| Sep 25, 2026 | 88.10 | 88.10 | 85.63 | 85.69 | 560.10K |
| Sep 24, 2026 | 87.46 | 87.46 | 82.93 | 87.09 | 1.73M |
| Sep 23, 2026 | 91.56 | 91.56 | 86.30 | 88.17 | 918.80K |
| Sep 22, 2026 | 91.53 | 93.58 | 89.90 | 91.97 | 1.22M |
| Sep 21, 2026 | 91.07 | 94.06 | 89.65 | 92.03 | 1.45M |
About Spyre Therapeutics
Spyre Therapeutics (SYRE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1636282.
SYRE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeffrey W. Albers | Director | Aug 10, 2026 |
| Funds Management Llc Fairmount | Director | Jun 23, 2026 |
| Healthcare Fund Ii L.P. Fairmount | Director | Jun 23, 2026 |
| Michael Thomas Henderson | Director | Jun 23, 2026 |
| Peter Evan Harwin | Director | Jun 23, 2026 |
| Tomas Kiselak | Director | Jun 23, 2026 |
| Mark C. Mckenna | Director | May 29, 2026 |
| Sandra Milligan | Director | May 29, 2026 |
| Laurie Stelzer | Director | May 29, 2026 |
| Cameron Turtle | Chief Executive Officer | Sep 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Scott L Burrows | Chief Financial Officer | Sep 3, 2026 |
| Heidy King-Jones | See Remarks | Sep 3, 2026 |
| Sheldon Sloan | Chief Medical Officer | Jul 2, 2026 |
| Cameron Turtle | Chief Executive Officer | Sep 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Scott L Burrows | Sale | 18,232 | $89.35 |
| Sep 2, 2026 | Scott L Burrows | Sale | 18,232 | $89.35 |
| Sep 2, 2026 | Scott L Burrows | Sale | 18,232 | $89.35 |
| Sep 2, 2026 | Scott L Burrows | Sale | 18,232 | $89.35 |
| Sep 2, 2026 | Heidy King-Jones | Sale | 400 | $90.00 |
| Sep 2, 2026 | Heidy King-Jones | Sale | 400 | $90.00 |
| Sep 2, 2026 | Heidy King-Jones | Sale | 400 | $90.00 |
| Sep 2, 2026 | Heidy King-Jones | Sale | 400 | $90.00 |
| Sep 1, 2026 | Scott L Burrows | Sale | 200 | $89.04 |
| Sep 1, 2026 | Scott L Burrows | Sale | 2,016 | $88.03 |
| Sep 1, 2026 | Scott L Burrows | Sale | 900 | $86.25 |
| Sep 1, 2026 | Scott L Burrows | Sale | 4,384 | $87.11 |
| Sep 1, 2026 | Scott L Burrows | Sale | 200 | $89.04 |
| Sep 1, 2026 | Scott L Burrows | Sale | 2,016 | $88.03 |
| Sep 1, 2026 | Scott L Burrows | Sale | 900 | $86.25 |
SYRE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-155.20M | — | $-169.25M |
| Dec 31, 2024 | $0 | $-208.02M | — | $-157.41M |
| Dec 31, 2023 | $886.00K | $-338.79M | -49.12 | $-99.91M |
| Dec 31, 2022 | $2.33M | $-83.81M | -24.86 | $-80.14M |
| Dec 31, 2021 | $18.74M | $-65.80M | -25.02 | $-53.72M |
Latest balance sheet: total assets $1.17B, total liabilities $71.86M, cash $162.01M (as of Jun 30, 2026).
SYRE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $104.94 |
| May 5, 2026 | 8-K Item 2.02 (results) | $71.01 |
| Apr 13, 2026 | 8-K Item 2.02 (results) | $63.27 |
| Feb 19, 2026 | 8-K Item 2.02 (results) | $37.81 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $22.98 |
| Oct 14, 2025 | 8-K Item 2.02 (results) | $21.00 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $16.87 |
| May 8, 2025 | 8-K Item 2.02 (results) | $12.86 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $18.37 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $21.55 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $37.69 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SYRE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.